Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Lumos Pharma
Providence Health & Services
Royal Marsden NHS Foundation Trust
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Incyte Corporation
Repare Therapeutics
Bristol-Myers Squibb
Incyte Corporation
Emory University
Gilead Sciences
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
Hoosier Cancer Research Network
M.D. Anderson Cancer Center
NanoCarrier Co., Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immodulon Therapeutics Ltd
University of Alabama at Birmingham
BioNTech SE
Altor BioScience
Altor BioScience
Hutchmed
Gilead Sciences
City of Hope Medical Center
Novo Nordisk A/S
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
MedImmune LLC
Eli Lilly and Company
Pfizer
EMD Serono
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eisai Inc.
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Kyntra Bio
Mereo BioPharma
Incyte Corporation
Incyte Corporation
University of Pittsburgh
Eli Lilly and Company
Eli Lilly and Company
Eisai Inc.
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Aadi Bioscience, Inc.